In 2022, fewer than one in five patients with new onset type 2 diabetes taking a glucose‐lowering medication utilized GLP‐1 receptor agonists or SGLT‐2 inhibitors in the year following their diagnosis. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.